{"_id": "64ffe6c7748b29c10bbbeb01", "nctId": "NCT04092283", "title": "Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC", "Not yet fixed MQL": "{\n\"and\": [\n{\n\"$or\": [\n{\"cancer type\": \"non-small cell lung cancer (NSCLC)\"},\n{\"cancer stage\": {\"$in\": [3, 4]}}\n]\n},\n{\"resectable\": false},\n{\"pathologically confirmed\": true},\n{\"nodal recurrence after surgery for early stage NSCLC\": true},\n{\"ECOG status\": {\"$in\": [0, 1]}}\n],\n\"body weight\": {\"$gt\": 30},\n\"unintentional weight loss\": {\"$lte\": 10},\n\"baseline electrocardiography (ECG)\": {\"$lte\": 6},\n\"measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1\": {\"$lte\": 4},\n\"Absolute neutrophil count (ANC)\": {\"$gte\": 1500},\n\"White blood cells (WBC) counts\": {\"$gte\": 2500},\n\"Platelet count\": {\"$gte\": 100000},\n\"Hemoglobin\": {\"$gte\": 9.0},\n\"Total bilirubin\": {\"$lte\": 1.5},\n\"Aspartate aminotransferase (AST) and alanine transaminase (ALT)\": {\"$lte\": 3.0},\n\"Serum creatinine\": {\"$lte\": 1.5},\n\"pulmonary function tests (PFTs) with both forced expiratory volume in 1 second (FEV1) and diffusion capacity of the lung for carbon monoxide (DLCO)\": {\"$gte\": 40},\n\"lung volume (V)20\": {\"$lte\": 35},\n\"$or\": [\n{\n\"$and\": [\n{\"nodal recurrence after surgery for early-stage NSCLC\": true},\n{\"No prior chemotherapy or radiation was ever administered for this lung cancer originally or for recurrence prior to entering this protocol\": true},\n{\"Prior curative-intent surgery was at least 90 days prior to the nodal recurrence\": true},\n{\"No prior radiation was administered to the region of study cancer that would cause overlap of treatment fields\": true}\n]\n},\n{\n\"$and\": [\n{\"human immunodeficiency virus (HIV) positive\": true},\n{\"stable on their anti-retroviral regimen\": true},\n{\"healthy from an HIV perspective\": true},\n{\"CD4 count\": {\"$gt\": 250}},\n{\"not receiving prophylactic therapy for an opportunistic infection\": true}\n]\n},\n{\"prior or concurrent malignancy\": true},\n{\"chemotherapy or radiotherapy within 4 weeks\": false},\n{\"pregnant or breast-feeding\": false},\n{\"negative blood test or urine study\": true},\n{\"expected to conceive or father children\": false}\n]\n},\n{\n\"$not\": {\n\"$or\": [\n{\"active, known or suspected autoimmune disease and neuromuscular paraneoplastic syndromes\": true},\n{\"history of active hepatitis B or hepatitis C infection\": true}\n]\n}\n}\n]\n}"}